Transforming growth factor b activated kinase-1 (TAK1), a member of the mitogen-activated protein kinase kinase kinase family, has emerged as a key regulator of signal transduction cascades leading to the activation of the transcription factors nuclear factor-kappa B (NF-jB) and activator protein-1 (AP-1). Stimulation of cells with cytokines and microbial pathogens results in the activation of TAK1, which subsequently activates the I-kappa B kinase complex (IKK) and mitogen-activated protein (MAP) kinases, culminating in the activation of NF-jB and AP-1, respectively. Recent studies have shown that polyubiquitination of signalling proteins through lysine (Lys)-63-linked polyubiquitin chains plays an important role in the activation of TAK1 and IKK. Unlike Lys-48-linked polyubiquitination, which normally targets proteins for degradation by the proteasome, Lys-63-linked polyubiquitin chains act as scaffolds to assemble protein kinase complexes and mediate their activation through proteasome-independent mechanisms. The concept of ubiquitin-mediated activation of protein kinases is supported by the discoveries of ubiquitination and deubiquitination enzymes as well as ubiquitin-binding proteins that function upstream of TAK1 and IKK. Recent biochemical and genetic studies provide further insights into the mechanism and function of ubiquitin signalling and these advances will be the focus of this review.
Introduction
The nuclear factor-kappa B (NF-kB) pathway has been a subject of intense studies since its discovery about two decades ago (Sen and Baltimore, 1986a, b) . It is now well established that the NF-kB family of transcription factors controls a variety of physiological and pathological processes, including inflammation, immunity and cell survival. For NF-kB to exert such an important role, its activity must be tightly regulated. This is achieved largely by retaining NF-kB in the cytoplasm of unstimulated cells, and sending it to the nucleus upon stimulation. NF-kB is sequestered in the cytoplasm through its association with an inhibitory protein of the IkB (inhibitors of NF-kB) family, which masks the nuclear localization signal of NF-kB. Stimulation of cells with a variety of agents, including proinflammatory cytokines such as tumor necrosis factor-a (TNFa) and interleukin 1-b (IL-1b), and microbial products such as lipopolysaccharide (LPS), leads to the activation of the IkB kinase (IKK) complex, which is composed of the catalytic subunits IKKa and IKKb, and the essential regulatory subunit NEMO (also known as IKKg or IKKAP). IKK phosphorylates the IkB proteins and targets these inhibitors for degradation by the ubiquitin-proteasome pathway, thus allowing NF-kB to enter the nucleus to turn on a large array of target genes (Scheidereit, 2006) .
The central role of IKK in mediating NF-kB activation in response to diverse pathways has been demonstrated through biochemical and genetic studies. However, the mechanisms by which IKK is regulated by different signalling pathways have just begun to unfold. Among different NF-kB signalling pathways, those emanating from the receptors of IL-1b and TNFa have been most extensively studied. In the IL-1b pathway, binding of IL-1b to its receptor leads to the recruitment of signalling proteins including MyD88, IRAK1, IRAK4 and TRAF6 (Figure 1 ). TRAF6 is a RING domain ubiquitin ligase that catalyses the synthesis of a polyubiquitin chain linked through lysine (Lys)-63 (K63) of ubiquitin (Deng et al., 2000) . This K63 polyubiquitination activates the transforming growth factor b activated kinase-1 (TAK1) kinase complex, which phosphorylates IKKb at key serine residues in the activation loop, resulting in IKK activation (Wang et al., 2001) . TAK1 also phosphorylates members of the MKK family, which in turn phosphorylates and activates JNK (Jun N-terminal kinase) and p38 kinases Wang et al., 2001) . In the TNFa pathway, the binding of TNFa to its receptor leads to the rapid recruitment of signal adapter proteins including TRADD, TRAF2, TRAF5 and receptor interacting protein (RIP)1. TRAF2 and TRAF5 are also RING domain proteins and likely function as ubiquitin ligases to promote the polyubiquitination of RIP1. The ubiquitinated RIP1 then activates TAK1 and IKK, leading to NF-kB activation (Chen, 2005; Krappmann and Scheidereit, 2005; Kovalenko and Wallach, 2006) .
Although the framework of ubiquitin-mediated activation of TAK1 and IKK was established based on biochemical studies, the mechanisms and physiological functions of ubiquitin signalling were not clear. Recent studies have provided new insights into the mechanisms of ubiquitin signalling through the discovery of ubiquitin-binding proteins that turn out to be essential regulatory subunits of TAK1 and IKK. In addition, the identification of deubiquitination enzymes, including CYLD and A20, which negatively regulate IKK and JNK, offers further support to the regulatory role of ubiquitination in protein kinase activation. Genetic studies of TAK1 and ubiquitination enzymes confirm their importance in the IKK and JNK signalling pathways, but also reveal complexities inherent in these pathways that invite further exploration. Figure 1 Ubiquitin-mediated activation of TAK1 and IKK in innate and adaptive immunity pathways. Stimulation of TNFR1 leads to the activation of ubiquitin ligase activities of TRAF2 and TRAF5, which then promote the K63-polyubiquitination of RIP1 in the presence of E1 and the Ubc13/Uev1A E2 complex. The polyubiquitinated RIP1 recruits the TAK1 kinase complex through the interaction between the K63 polyubiquitin chains and TAB2 or TAB3. The polyubiquitin chains also recruit IKK by binding to NEMO, thus allowing TAK1 to phosphorylate and activate IKK. IKK phosphorylates IkB and targets this inhibitor for degradation by the proteasome, allowing NF-kB to enter the nucleus to turn on downstream target genes, which include mediators of immune and inflammatory responses as well as feedback inhibitors of the NF-kB pathway. Two of these inhibitors are deubiquitination enzymes CYLD and A20, which can remove K63 polyubiquitin chains from TRAF proteins and RIP1, thus suppressing IKK activation. A20 can also function as an E3 to promote K48 polyubiquitination of RIP1, which targets it for degradation by the proteasome. The IL1R and TLR signalling pathways activate IKK through TRAF6, which functions as a ubiquitin E3 as well as a target of K63 polyubiquitination. The polyubiquitinated TRAF6 recruits TAK1 and IKK complexes to mediate the activation of these kinases. In the TCR and BCR signalling pathways, the engagement of these receptors by antigens triggers a signalling cascade that leads to the recruitment of a protein complex consisting of CARMA1, BCL10 and MALT1. MALT1 binds to and promotes the oligomerization of TRAF2 and TRAF6. These E3 enzymes then activate TAK1 and IKK through a mechanism similar to that operating in the innate immunity pathways.
Ubiquitination enzymes involved in the activation of TAK1 and IKK

Ubiquitin-conjugating enzymes (E2)
Biochemical fractionation studies, aimed at identifying the molecular components required for TRAF6-mediated activation of IKK, led to the isolation of the following two active fractions from HeLa cell extracts: TRIKA1 (TRAF6-regulated IKK activator 1 and TRIKA2 (Deng et al., 2000) . Further purification and mass spectrometric analysis showed that TRIKA1 is a heterodimeric ubiquitin-conjugating enzyme (E2) complex consisting of Ubc13 and the Ubc-like protein Uev1A. Using ubiquitin mutants, in which all seven Lys residues of ubiquitin were mutated to arginine individually or in combination, it was shown that the Ubc13/ Uev1A complex specifically catalyses the formation of K63-linked polyubiquitin chains (Hofmann and Pickart, 1999; Deng et al., 2000) .
The molecular basis of K63-linkage-specific synthesis of polyubiquitin chains by Ubc13/Uev1A has been revealed through structural studies of Ubc13 in complex with the yeast homolog of Uev1A known as Mms2 (VanDemark et al., 2001 ). Ubc13 and Mms2 form an asymmetric heterodimer and display overall folds similar to those of canonical E2 enzymes. The overall orientation of the subunits allows covalent attachment of a 'donor' ubiquitin to the active site of Ubc13 and binding of an 'acceptor' ubiquitin to Mms2 in such a way that only K63 of the acceptor ubiquitin is oriented toward the carboxyl terminus of the donor ubiquitin. This model is further supported by the recent crystal structure of Ubc13/Mms2 covalently bound to ubiquitin (Eddins et al., 2006) . This structure not only revealed a 'donor' ubiquitin covalently linked to the Ubc13 active site but also showed that ubiquitin from a neighboring complex interacts with Mms2. The interaction of Mms2 with the adjacent ubiquitin positions K63 of this ubiquitin in close proximity to the thioester bond between Ubc13 and the 'donor' ubiquitin. Mutations of key residues in Mms2, which are involved in binding to the 'acceptor' ubiquitin, severely disrupt the catalytic activity of Ubc13/Mms2 complex. These structural studies revealed an elegant mechanism by which Mms2 can orient ubiquitin to specifically promote the formation of K63-linked polyubiquitin chains by Ubc13.
Unlike K48 polyubiquitin chains that normally target proteins for degradation by the proteasome (Chau et al., 1989) , K63 polyubiquitination has been shown to exert signalling functions independent of proteasomal degradation; these functions include DNA repair, vesicle trafficking and protein kinase activation . The structural studies of diubiquitin linked either through K48 or K63 of ubiquitin provides important insights into the molecular basis of ubiquitin signalling. K48-linked diubiquitin adopts a closed conformation where certain surface hydrophobic residues of ubiquitin form interubiquitin contacts (Cook et al., 1992) . On the other hand, K63-linked diubiquitin displays an 'open' conformation with very little contact between the individual ubiquitin modules (Varadan et al., 2004) .
The structural differences between K48-and K63-linked diubiquitin may underlie the distinct signalling functions of different polyubiquitin chains. It should be noted that K63-linked ubiquitinated proteins could still be degraded by the proteasome in vitro . Thus, the resistance of K63-linked polyubiquitinated proteins to proteasome in vivo can be a result of sequestration of the K63-linked polyubiquitin tag by the ubiquitin-binding proteins (see below).
Ubc13 and Uev1A are highly conserved from yeast to human. The yeast homologue of this E2 complex, Ubc13/Mms2, catalyses K63 polyubiquitination that is required for stress response and DNA repair. Yeast strains carrying the K63R mutation of ubiquitin and those lacking Ubc13 or Mms2 are highly sensitive to UV-or chemical-induced DNA damage (Spence et al., 1995; Hofmann and Pickart, 1999) . These phenotypes are dramatically different from those of K48R mutants, which display a global defect in protein turnover (Chau et al., 1989) . These genetic experiments provide the in vivo evidence that K63 polyubiquitination have functions distinct from K48 polyubiquitination.
An evolutionarily conserved role of Ubc13 and Uev1A in innate immune response was provided by recent experiments in Drosophila, which possesses an anti-bacterial pathway similar to that of the NF-kB pathway in mammals (Kaneko and Silverman, 2005; Zhou et al., 2005) . In this pathway, the bacterial peptidoglycans activate the Drosophila homologue of IKK (dIKK), which phosphorylates the NF-kB-like transcription factor precursor Relish. Relish is then cleaved into a mature transcription factor, which enters the nucleus to induce the expression of a battery of antibacterial peptides. RNA interference (RNAi) of the Drosophila homologues of Ubc13 and Uev1A diminished the activation of dIKK and the induction of antibacterial peptides. Furthermore, the Drosophila mutant Bendless, which harbours a point mutation in a conserved region of dUbc13, is compromised in inducing anti-bacterial peptides in response to Escherichia coli infection (Muralidhar and Thomas, 1993; Zhou et al., 2005) .
The role of Ubc13 in mammalian immune response has been investigated through the deletion of Ubc13 in mice. As the conventional Ubc13 knockout mice were early embryonic lethal, conditional knockout of Ubc13 was generated (Yamamoto et al., 2006a) . Loss of Ubc13 in fibroblasts and B cells caused a severe defect in the activation of mitogen-activated protein (MAP) kinases including JNK, p38 and extracellular signal-regulated kinase (ERK) in response to IL-1b, several ligands of toll-like receptors (TLR), CD40 and B-cell receptors (BCRs). The development and activation of B cells were impaired in the absence of Ubc13. Surprisingly, MAPK activation by TNFa was not affected in the Ubc13 mutant cells. Furthermore, the deficiency in Ubc13 only delayed the activation of TAK1 and had little effect on the activation of IKK and NF-kB. The defect in the activation of JNK and p38 was attributed to the loss of NEMO ubiquitination and it was proposed that ubiquitination of NEMO is required for the activation of JNK and p38. However, other studies have shown that IKK and NF-kB suppress JNK activation (Papa et al., 2006) . It should be noted that the Ubc13 knockout cells were not completely devoid of the Ubc13 protein (Yamamoto et al., 2006a) . The genome projects predict that there are three Ubc13-like genes in mouse, which are located in chromosomes 10, 7 and X, respectively. Only the Ubc13 gene on chromosome 10 was targeted in the reported knockout study. Similarly, two Ubc13-like genes are located in human chromosomes 12 and X, respectively. The normal activation of IKK and NF-kB may also be due to the presence of other E2s which function redundantly with Ubc13 to mediate the activation of IKK. In fact, when the IKK complex was discovered in 1996, it was shown that this kinase could be activated in vitro by a ubiquitination reaction involving an E2 of the Ubc4/5 family (Chen et al., 1996) .
In contrast to embryonic fibroblasts and B cells, conditional excision of the Ubc13 locus in T cells led to a more complete depletion of the Ubc13 protein (Yamamoto et al., 2006b). Correspondingly, there was a severe defect of IKK and NF-kB activation in Ubc13-deficient thymocytes in response to T-cell receptor (TCR) stimulation. In addition, TCR-induced activation of TAK1 and JNK and proliferation of thymocytes were blocked in the absence of Ubc13, whereas the activation of other kinases such as protein kinase C (PKC)y and ERK was normal. As the Ubc13/Uev1A E2 complex only catalyses K63 polyubiquitination, these results formally demonstrate the essential role of K63 polyubiquitination in protein kinase activation in T cells. The role of ubiquitination in TCR signalling will be discussed in more details in the following section.
The TRAF family of ubiquitin-protein ligases (E3)
The realization that Ubc13/Uev1A is an E2 complex that can activate IKK led to the discovery of TRAF6 as a ubiquitin ligase (Deng et al., 2000) . Indeed, TRAF6 and several other members of the TRAF family of proteins contain a highly conserved RING domain that is now known to be present in a large family of ubiquitin ligases (Petroski and Deshaies, 2005) . In addition to the RING domain, TRAF proteins also contain zincfinger domains, a coiled-coil region and a C-terminal TRAF homology domain that interacts with upstream signalling proteins (Chung et al., 2002) . RING domain-containing E3 enzymes do not directly participate in the catalysis of ubiquitination, but allosterically activate E2 enzymes and recruit ubiquitination substrates to E2.
In overexpression studies, the RING domains of TRAF6 and TRAF2 are indispensable for the activation of NF-kB and JNK (Cao et al., 1996; Baud et al., 1999) . In experiments employing TRAF6 mutants to complement TRAF6-deficient cells, it was found that the removal of the RING domain impaired the activation of MAPK by IL-1b and LPS, and prevented the maturation of osteoclasts (Kobayashi et al., 2001 ).
However, the RING domain deletion had little effect on the activation of NF-kB despite the loss of TAK1 activation. This result suggests that IKK can still be activated in the absence of TAK1, which is incompatible with recent experiments showing that TAK1 is required for IKK activation by multiple pathways (see below). In a more recent study, Lamothe et al. (2007) showed that a point mutation (C70A) within the RING domain of TRAF6, which abrogated its ubiquitin E3 activity, severely impaired TAK1 and IKK activation by IL-1b in similar complementation experiments. It is not clear why the two studies arrived at different conclusions concerning the role of the E3 activity of TRAF6 in IKK activation. Further studies on TRAF6 and other TRAF proteins are required to clarify the role of ubiquitination by TRAF proteins.
TRAF6 is essential for the activation of NF-kB and AP-1 by multiple pathways, including those of IL-1b, IL-18, CD40, RANK and all TLRs except TLR3 (Wu and Arron, 2003) . On the other hand, TRAF2 is required for signalling by members of the TNF-receptor family. The TRAF2-deficient cells exhibit a severe defect in JNK, but not NF-kB, activation in response to TNFa stimulation (Lee et al., 1997; Yeh et al., 1997) . The normal activation of NF-kB in TRAF2-deficient cells is due to the redundancy between TRAF2 and TRAF5, as cells lacking both TRAF2 and TRAF5 are defective in NF-kB activation by TNFa (Tada et al., 2001) . It has been shown that the RING domain of TRAF2 is important for NF-kB activation Baud et al., 1999) , but this needs to be more rigorously tested in an in vivo model. TRAF3 also contains an N-terminal RING domain but it functions as an inhibitor of the NF-kB pathway (Hauer et al., 2005) . Interestingly, TRAF3 is essential for signalling by a subfamily of TLRs, including TLR3, TLR7 and TLR9, to activate the IKK-like kinases TRAF-associated NF-kB activator (TANK)-binding kinase (TBK)1 and IKKe (Hacker et al., 2006; Oganesyan et al., 2006) . These kinases phosphorylate the transcription factors IRF3 and IRF7 to induce type-I interferons (IF) in response to viral infection (Fitzgerald et al., 2003; Sharma et al., 2003) . Viral RNA in the cytosol can also induce interferons by activating a signalling pathway through the RNA helicase proteins RIG-I and MDA5 (Yoneyama et al., 2004) . These proteins interact with the mitochondrial anti-viral signalling protein (MAVS) (also known as IPS-1, CARDIF or VISA Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005) . MAVS contains binding sites for TRAF proteins including TRAF2, TRAF6 and TRAF3. TRAF2 and TRAF6 are likely to mediate the activation of IKK and NF-kB, whereas TRAF3 activates TBK1 and IRF3 (Saha and Cheng, 2006; Seth et al., 2006) . The coordinate activation of NF-kB and IRF3 leads to the induction of interferons to suppress viral replication and assembly. At present it is not clear whether ubiquitination plays a role in the activation of protein kinases by MAVS and TRAF proteins in the anti-viral pathways.
The TAK1 kinase complex TRIKA2, the second factor required for IKK activation by TRAF6, turns out to be a protein kinase complex containing the kinase subunit TAK1 and the regulatory subunits TAB1 and TAB2 (Wang et al., 2001) . TAK1 was first shown to be a transforming growth factor (TGF)-b-activated kinase, but subsequent experiments showed that it is also involved in the IL-1b signalling pathway (Yamaguchi et al., 1995; Ninomiya-Tsuji et al., 1999) . As a member of the MAP3K family, TAK1 is unique in that its activity requires its binding proteins TAB1, TAB2 and TAB3 (Shibuya et al., 1996; Takaesu et al., 2000; Ishitani et al., 2003; Cheung et al., 2004; Kanayama et al., 2004) . TAB1 contains an N-terminal pseudophosphatase domain, which is dispensable for TAK1 activation, and a C-terminal domain that binds to and activates TAK1 (Ono et al., 2001; Conner et al., 2006) . Although TAB1 can activate TAK1 directly in vitro, the endogenous TAK1 complex, which contains TAB1, is inactive in unstimulated cells. It is not clear what prevents TAK1 from being activated by TAB1 in cells, although some phosphatases have been shown to associate with and inhibit TAK1 (Li et al., 2003; Kajino et al., 2006) . TAB2 and its homologue TAB3 also activate TAK1 when they are overexpressed in cells. However, unlike TAB1, TAB2 and TAB3 do not activate TAK1 directly in vitro. Instead, the activation of the TAK1/TAB2 (or TAB3) complex requires a ubiquitination reaction catalysed by E1, Ubc13/Uev1A (E2) and TRAF6 (E3) (Wang et al., 2001) . The TAK1/ TAB2 (or TAB3) complex that is activated by ubiquitination can phosphorylate IKKb at serine (Ser)-177 and Ser-181 in the activation loop, leading to IKK activation. This activated TAK1 complex can also phosphorylate members of the MKK family, leading to the activation of JNK and p38 kinase. Interestingly, the TAK1/TAB1 complex, which can also phosphorylate MKKs and activate JNK and p38, is not sufficient to activate the IKK complex (Wang et al., 2001) . Thus, TAB2/3, but not TAB1, is required for IKK activation by TRAF6 in vitro. These results suggest that TRAF6-mediated ubiquitination is not only required for the activation of the TAK1 complex but also required for IKK activation by TAK1. The second step of ubiquitination requirement may be due to the binding of polyubiquitin chains by TAB2/3 and NEMO, which facilitates IKK activation by TAK1 (see below).
The essential role of TAK1 in innate immune responses was first demonstrated in Drosophila (Vidal et al., 2001) . The Drosophila TAK1 (dTAK1) mutants quickly succumb to Gram-negative bacterial infection and failed to produce anti-bacterial peptides. Genetic and biochemical experiments showed that dTAK1 is required for the activation of IKK and JNK (Silverman et al., 2003) . Similarly, the Drosophila homologue of TAB2 (dTAB2) is also required for the activation of JNK and NF-kB and the induction of anti-bacterial peptides (Geuking et al., 2005; Kleino et al., 2005; Zhuang et al., 2006) . Surprisingly, recent studies showed that neither dTAK1 nor dTAB2 is required for the processing of Relish, raising the possibility that TAK1 and IKK may control the activity of Relish at a step after its cleavage (Delaney et al., 2006) .
Genetic experiments using mouse models have demonstrated the central role of TAK1 in multiple signalling pathways. TAK1-deficient embryonic fibroblasts and B cells fail to activate NF-kB or JNK in response to stimulation by IL-1b, TNFa and ligands of several TLRs Shim et al., 2005) . These results reinforce earlier experiments showing that RNAi and chemical inhibitors of TAK1 blocked IKK and JNK activation by multiple pathways . In contrast to TAK1, deletion of TAB1 or TAB2 did not affect NF-kB activation by IL-1b or TNFa (Komatsu et al., 2002; Sanjo et al., 2003) . As biochemical experiments had shown that TAB1 is dispensable for IKK activation by TRAF6 in vitro (Wang et al., 2001) , it is likely that TAB1 is involved in other signalling pathways (e.g., TGF-b) instead of the NFkB pathway. The normal activation of NF-kB in TAB2 knockout cells may be due to compensation by TAB3, which is highly homologous to TAB2. In support of this notion, simultaneous knockdown of TAB2 and TAB3 by RNAi blocked IKK and JNK activation by TNFa and IL-1b (Ishitani et al., 2003; Kanayama et al., 2004) .
Conditional knockout of TAK1 in lymphocytes also confirms the important role of TAK1 in antigen receptor signalling, which was first discovered from the biochemical studies of TCR signalling . The engagement of TCR by the antigen-major histocompatibility complex triggers the activation of the tyrosine phosphorylation cascade that leads to the activation of PKCy (Weil and Israel, 2006) . Subsequently, a multiprotein complex, termed CBM, which contains the CARD domain proteins CARMA1 and BCL10 and the paracaspase MALT1, is recruited to the lipid rafts. Abnormal activation of each protein in the CBM complex through overexpression or chromosomal translocation causes the constitutive activation of NFkB and has been linked to human lymphomas, including large B-cell lymphoma and mucosa-associated lymphoid tissue (MALT) lymphoma (Rawlings et al., 2006) . MALT1 contains binding sites for TRAF2 and TRAF6 . When the CBM complex is recruited to the lipid rafts, MALT1 becomes oligomerized and its binding to TRAF6 promotes the oligomerization of TRAF6, which activates its ubiquitin ligase (E3) activity. The subsequent K63-polyubiquitination of TRAF6 activates the TAK1 kinase complex. TRAF6 also ubiquitinates NEMO, thus facilitating the activation of IKK and NF-kB. The T-cell signalling pathway, from Bcl10 to IkBa phosphorylation, was reconstituted in vitro using purified proteins including ubiquitination enzymes and the TAK1 kinase complex. In an independent study, it was shown that MALT1 is a ubiquitin E3 that directly catalyses the K63 polyubiquitination of NEMO, which mediates IKK activation .
The roles of TRAF6 and TAK1 in T-cell activation have recently been investigated by conditional knockout of these genes in the T-cell lineage (King et al., 2006) . Unexpectedly, the ablation of TRAF6 in T cells led to multiorgan inflammation owing to the hyperactivation of the phosphatidylinositol 3-kinase pathway, which renders T cells resistant to suppression by regulatory T cells. T cells lacking TRAF6 could still activate NF-kB and MAPK in response to TCR challenge. As RNAi of both TRAF6 and TRAF2 in Jurkat cells led to a more profound suppression of NF-kB than RNAi of either TRAF alone , it is likely that TRAF2 can compensate for the loss of TRAF6 in TCR signalling. A precedence for compensatory functions between two different proteins has recently been reported for JNK1 and JNK2: although the single knockout of JNK2 suggested that it is a negative regulator of c-Jun phosphorylation, chemical genetic studies showed that JNK2 is a positive regulator of c-Jun (Jaeschke et al., 2006) . In the case of TRAF2, transgenic mice harbouring a dominant negative mutant of TRAF2 displayed a profound defect in T-cell proliferation and IL-2 production following TCR stimulation (Lee et al., 1997; Cannons et al., 2002) . Thus, simultaneous deletion of TRAF2 and TRAF6 in T cells may shed light on the role of these proteins in TCR signalling.
Three independent studies have recently shown that conditional knockout of Tak1 in T cells leads to a severe defect in thymocyte development and activation Sato et al., 2006; Wan et al., 2006) . In particular, the development of regulatory T cells was abrogated in the Tak1 mutant mice, resulting in higher incidence of colitis (Sato et al., 2006) . In Tak1-deficient thymocytes, TCR failed to induce the activation of NF-kB and JNK. However, in effector T cells, TCRdependent activation of NF-kB was largely normal when the level of TAK1 was reduced (Wan et al., 2006) . A similar observation was found in B cells in which deletion of Tak1 abrogated the activation of JNK but not NF-kB by stimulation of BCR . In contrast to this report, however, another study showed that the deletion of Tak1 in the chicken DT40 B cell line by homologous recombination completely blocked IKK and JNK activation by BCR (Shinohara et al., 2005) . This latter study also showed that the BCR signalling pathway could be rescued by re-introducing the wildtype TAK1, but not the catalytically inactive mutant, back into the Tak1 null cell line, indicating that the kinase activity of TAK1 is essential.
In light of the biochemical and genetic evidence accumulated so far, it is clear that TAK1 plays a major role in the activation of IKK and JNK in the innate and adaptive immunity pathways. In this regard, TAK1 is an IKK kinase (IKKK). However, the extent of involvement by TAK1 in different pathways may depend on the cell types. For example, it was reported recently that the activation of NF-kB and JNK by TLR8 is TAK1-independent but MEKK3-dependent (Qin et al., 2006) . In MEKK3 knockout cells, there was a delay in the activation of NF-kB and JNK by TNFa, IL-1b and LPS (Yang et al., 2001; Huang et al., 2004) . In TAK1-deficient cells, although JNK activation by proinflammatory cytokines was completely abolished, the IKK activity was mostly but not completely blocked. Thus, a TAK1-independent mechanism may contribute to the residual activation of IKK. The TAK1-independent activation of IKK may be mediated by another kinase such as MEKK3, or through a mechanism independent of an upstream kinase. Although the TRAF6-interacting protein ECSIT (evolutionarily conserved signalling intermediate in Toll pathways) has been proposed to mediate the activation of NF-kB and JNK in the IL-1b and TLR pathways (Kopp et al., 1999) , RNAi of ECSIT in Drosophila or mammalian cells had no effect on the activation of NF-kB or JNK by any known ligands tested (M Hong and Z Chen, unpublished data). It was suggested that ECSIT binds to and activates MEKK1, which in turn activates IKK (Kopp et al., 1999) . However, genetic studies have shown that MEKK1 is dispensable for NF-kB activation (Yujiri et al., 2000) . Mouse knockout experiments showed that ECSIT is required for BMP signalling but so far there is no genetic evidence that it is required for NF-kB or MAPK activation (Xiao et al., 2003) .
The physiological role of TAK1 is not limited to NFkB and AP-1 activation. TAK1 is activated by ligands of the TGF-b family and has been shown to participate in mesoderm induction and patterning in early embryos (Shibuya et al., 1998) . In addition, TAK1 is activated by Wnt1 in a TAB1-dependent manner, and the activation of TAK1 leads to the downregulation of the Wnt signalling pathway (Ishitani et al., 1999; Smit et al., 2004) . Recent studies have also shown that TAK1 is required for the phosphorylation and activation of adenosine monophosphate (AMP)-activated kinase, which regulates energy sensing (Momcilovic et al., 2006; Xie et al., 2006) . Thus, TAK1 has emerged as a central regulator of diverse physiological processes including development, metabolism, and immune and stress responses. Understanding how this central regulator is regulated in different pathways will be an exciting area of future research.
Ubiquitination targets and polyubiquitin adapters in the activation of TAK1 and IKK
Ubiquitination targets
Free K63 polyubiquitin chains that are not anchored to a protein target cannot activate IKK. Instead, they function as a dominant-negative inhibitor (Deng et al., 2000) , suggesting that polyubiquitination of target proteins is required for IKK activation. In recent years, several signalling proteins in the NF-kB pathway have been shown to be polyubiquitinated in a signaldependent manner. Stimulation of cells with IL-1b leads to the polyubiquitination of IRAK1 and TRAF6. Ubiquitination of IRAK1 is thought to target its degradation by the proteasome (Jiang et al., 2002) . In addition, overexpression of TRAF6 can activate NF-kB in IRAK1-deficient cells, suggesting that ubiquitination of IRAK1 may not be required for NF-kB activation (Li et al., 1999) . The kinetics of IL-1b-induced polyubiquitination of TRAF6 correlates with the activation of IKK. In addition, forced dimerization of TRAF6 using a small molecule dimerizer induces the polyubiquitination of TRAF6 and concomitant activation of IKK (Wang et al., 2001) . A recent study has identified Lys-124 of TRAF6 as the major site of autoubiquitination (Lamothe et al., 2007) . A point mutation at Lys-124 abolishes the ability of TRAF6 to activate TAK1 and IKK, providing the direct evidence that autoubiquitination of TRAF6 is required for signaling to downstream kinases.
In the TNFa pathway, the protein kinase RIP1 has been shown to undergo polyubiquitination following TNFa stimulation (Zhang et al., 2000; Legler et al., 2003; Kanayama et al., 2004; Wertz et al., 2004) . Ubiquitination of RIP1 was not detected in TRAF2-deficient cells, suggesting that TRAF2 might function as an E3 for RIP1 . RIP1 contains a kinase domain, which is dispensable for NF-kB activation, and an intermediate domain, which is required for signalling. Recently, the ubiquitination site of RIP1 was mapped to Lys-377, which is localized within the intermediate domain (Ea et al., 2006; Li et al., 2006) . A point mutation at Lys-377 of RIP1 abolished its ubiquitination as well as its ability to activate IKK, indicating that ubiquitination of RIP1 is required for IKK activation. TRAF2 has also been reported to undergo auto-polyubiquitination, which has been linked to the activation of JNK by TNFa (Shi and Kehrl, 2003) . The ubiquitination site of TRAF2 has not been identified yet, so the physiological role of TRAF2 autoubiquitination requires further investigation.
NEMO is a common target of polyubiquitination in response to stimulation in diverse signalling pathways. In response to TNFa stimulation, NEMO was found to be polyubiquitinated in a manner that depends on an intact zinc-finger domain (Tang et al., 2003) . Mutations within this domain have been found in patients with hypohidrotic ectodermal dysplasia with immunodeficiency (HED-ID) (Courtois and Gilmore, 2006) . Overexpression experiments using ubiquitin mutants led to the conclusion that NEMO is modified by K6-linked polyubiquitin chains (Tang et al., 2003) . In contrast, stimulation of TCR leads to K63 polyubiquitination of NEMO at K399 within the zinc-finger domain, and this modification may be carried out by MALT1 directly or indirectly through TRAF6 and/or TRAF2 Zhou et al., 2004) . Ubc13 is responsible for the TCR-induced ubiquitination of NEMO, and this has been confirmed by genetic experiments in Ubc13-deficient T cells (Yamamoto et al., 2006b) . NEMO is also modified by K63 polyubiquitin chains following stimulation of cells with agonists of NOD2, an intracellular signalling protein that has been linked to Crohn's disease in human (Abbott et al., 2004) . The site of NEMO modification has been mapped to Lys-285, and this modification requires the protein kinase RIP2.
Ubiquitination of NEMO also plays an important role in NF-kB activation by DNA damaging agents (Huang et al., 2003) . Although the majority of NEMO is associated with the catalytic IKK subunits in the cytosol, a small fraction of NEMO is found in the nucleus. This nuclear pool of NEMO is modified by SUMO, a ubiquitin-like protein, in response to genotoxic stress. The sumoylation of NEMO requires the death domain proteins PIDD and RIP1 as well as the SUMO E3 PIASy (Janssens et al., 2005; Mabb et al., 2006) . The sumoylated NEMO is phosphorylated by ATM, which is activated by DNA double-strand break. This phosphorylation event promotes the replacement of the SUMO with monoubiquitin at the same sites, K277 and K309, on NEMO (Huang et al., 2003) . The ubiquitinated NEMO is then exported to the cytoplasm, along with ATM, to mediate the activation of IKK (Wu et al., 2006b) . It is still not clear how monoubiquitination of NEMO leads to the activation of IKK in the cytosol. One possibility is that the ubiquitin on NEMO may be further extended by K63 polyubiquitin chains, resulting in the activation of IKK.
At present, it is not clear why NEMO is ubiquitinated at different sites in response to different stimuli. It should also be noted that although ubiquitination of NEMO may contribute to IKK activation, it does not explain how TAK1 and JNK are activated by K63 polyubiquitination because NEMO is not required for TAK1 or JNK activation. Thus, ubiquitination of signalling components upstream of TAK1, such as TRAF2, TRAF6 or RIP1, is likely to be important for the activation of TAK1 and JNK.
Ubiquitin receptors
Several proteins that can bind preferentially to K63 polyubiquitin chains have recently been identified. Interestingly, these proteins are regulatory subunits of TAK1 and IKK, namely TAB2/3 and NEMO, respectively. TAB2 and TAB3 contain two ubiquitin-binding domains: an N-terminal CUE domain (Cue1-homologous) and the C-terminal novel zinc-finger (NZF) domain (Kanayama et al., 2004) . Although the Nterminal CUE domain is dispensable for NF-kB activation by TAB2, the NZF domain is essential. This NZF domain binds to K63 polyubiquitin chains more strongly than it does to K48 chains or monoubiquitin. Deletion or mutations of the NZF domain abolished TAK1 and IKK activation, whereas the replacement of the NZF domain with a heterologous ubiquitin-binding domain restored kinase activation. The structural basis of K63-linkage-specific recognition by TAB2 and TAB3 is currently unknown.
Two recent studies have independently identified NEMO as a ubiquitin receptor that binds preferentially to K63 polyubiquitin chains (Ea et al., 2006; Wu et al., 2006a) . The ubiquitin-binding has been mapped to a region of about 66 amino acids spanning the coiled-coil domain and leucine zipper of NEMO. The primary sequence of this domain does not resemble any known ubiquitin-binding domain and is thus termed NUB (NEMO ubiquitin-binding) domain. Interestingly, the same domain has previously been shown to mediate the trimerization of NEMO (Agou et al., 2004) , suggesting that NEMO may bind to K63 polyubiquitin chains as a trimer or higher order oligomer. Mutations within the NUB domain that abrogate the binding of NEMO to K63-linked polyubiquitin chains also blocked TNFamediated activation of IKK. Based on these results, a model for IKK activation by TNFa was proposed (Figure 1) . In response to TNFa stimulation, which triggers K63 polyubiquitination of RIP1, NEMO binds to polyubiquitinated RIP1, thus facilitating the recruitment of the IKK complex to the TNF receptor. Polyubiquitinated RIP1 also recruits the TAK1 kinase complex through the binding between K63 polyubiquitin chains and TAB2. Thus, the K63 polyubiquitin chains on RIP1 serve as a scaffold to recruit the TAK1 and IKK complexes, allowing TAK1 to phosphorylate and activate IKK.
As NEMO can be a ubiquitin receptor as well as a ubiquitination target, it is not clear whether both functions of NEMO are important for signalling. Although mutations that affect NEMO's binding to polyubiquitin block IKK activation, these mutations also impair the ubiquitination of NEMO. Such a coupling between ubiquitin-binding and ubiquitination has also been observed in several other proteins, such as those involved in endosome trafficking (Hicke et al., 2005) . There is also no compelling evidence that abrogation of NEMO ubiquitination completely blocks IKK activation. Although mutations at K277 and K309 of NEMO inhibited IKK activation by genotoxic agents, K309 is located within the NUB domain and it has not been ruled out that the mutation of this residue may affect ubiquitin-binding. More studies are needed to clarify the role of ubiquitination of NEMO and ubiquitin-binding by NEMO in the activation of IKK.
Deubiquitination enzymes inhibit TAK1 and IKK
If K63-linked polyubiquitination is viewed as an 'on' switch for TAK1 and IKK, deubiquitination serves as an 'off' switch to restore the kinases to the basal states. CYLD and A20 are two of the best-studied deubiquitinating (DUB) enzymes that negatively regulate NF-kB upstream of IKK. CYLD is a tumour suppressor protein implicated in the development of familial cylindromatosis, a human skin tumour (Bignell et al., 2000) . The tumour-associated mutations in CYLD are frequently found in the C-terminal region, which contains a ubiquitin-carboxy-terminal-hydrolase (UCH) domain. Through this UCH domain, CYLD removes K63-linked polyubiquitin chains from several proteins, such as TRAF2, TRAF6 and NEMO, thereby suppressing NF-kB activation. Therefore, the loss-of-function of CYLD may lead to persistent activation of NF-kB to promote the survival of cancer cells (Brummelkamp et al., 2003; Kovalenko et al., 2003; Trompouki et al., 2003) . Three groups have recently reported the phenotypes of CYLD knockout mice, which surprisingly are not identical (Massoumi et al., 2006; Reiley et al., 2006; Zhang et al., 2006) . Massoumi et al. (2006) showed that CYLD-deficient mice are prone to chemical-induced skin cancer, owing, in part, to enhanced K63-polyubiquitination of BCL3, an IkB-like protein that functions as a transcriptional coactivator by forming a complex with the p50 or p52 subunit of NF-kB. Ubiquitination of BCL3 facilitates its nuclear accumulation, resulting in the activation of its target genes including cyclin D1, which promotes oncogenesis. The CYLD mutant mice generated by Zhang et al. (2006) were highly susceptible to chronic inflammation and colitis-associated cancer. Cells derived from these mice displayed increased ubiquitination of TRAF2 and NEMO as well as enhanced activation of IKK and JNK in response to TNFa stimulation. In the third report, Reiley et al. (2006) observed defective T-cell development in their CYLD knockout mice and they found that CYLD associates with and deubiquitinates LCK, a tyrosine kinase essential for T-cell activation. The loss of CYLD led to the enhanced polyubiquitination of LCK, which was then degraded by the proteasome. Surprisingly, in this model, CYLD-deficient cells had normal, rather than enhanced activation of NF-kB and JNK in response to stimulation by TNFa or LPS. It is not clear what caused the disparate phenotypes observed by different groups but these differences may reflect the limitations of mouse genetic studies, which could lead to different conclusions as a result of differences in targeting strategy, environment and genetic backgrounds.
Like CYLD, A20 is a potent inhibitor of IKK and a target gene of NF-kB (Krikos et al., 1992; Jono et al., 2004) . The induction of CYLD and A20 by NF-kB provides a negative feedback loop to regulate NF-kB activity. The A20-deficient mice developed spontaneous inflammation in multiple organs, owing to the hyperactivation of IKK and NF-kB (Lee et al., 2000) . A20 contains an OTU-type (ovarian tumour type) DUB domain in its N-terminal region and seven zinc-finger domains in the C-terminal region. Although the OTU domain is involved in removing K63-linked polyubiquitin chains from TRAF6 and RIP1 (Boone et al., 2004; Wertz et al., 2004) , the zinc-finger domains were reported to harbour E3 ubiquitin ligase activity to attach K48-linked polyubiquitin chains to RIP1 . Thus, A20 suppresses IKK activation by first removing K63-linked ubiquitin chains and then targeting RIP1 for degradation. However, it is known that overexpression of A20 mutants lacking the N-terminal OTU domain could still inhibit NF-kB activation (Evans et al., 2004) , suggesting that the zinc-finger domains may have inhibitory activities that do not require the removal of the K63 ubiquitin chains by the DUB activity. In this regard, recent crystallographic studies of an A20-type zinc-finger domain found in Rabex5 showed that this domain binds to ubiquitin at a unique surface that is usually not contacted by other ubiquitin-binding domains (Lee et al., 2006; Penengo et al., 2006) . The potential binding of A20 to ubiquitin or polyubiquitin chains may add another layer of complexity to the regulation of IKK by A20.
Conclusions and perspectives
A network of polyubiquitin-mediated protein-protein interactions plays an important role in the activation of IKK and TAK1. The major components of ubiquitin signalling include K63-linkage-specific E2 complex (Ubc13/Uev1A), ubiquitin E3 ligases (TRAFs), ubiquitination targets (TRAFs, RIP1 and NEMO), polyubiquitin-binding proteins (TAB2, TAB3 and NEMO) and DUB (CYLD and A20). Although the specific role of individual components of the ubiquitin signalling machinery may vary to some extent in different signalling pathways, a common theme is emerging and it involves the following steps: (1) activation of the TRAF E3 ligases by upstream signalling pathways, possibly through signal-induced oligomerization; (2) K63-linked polyubiquitination of target proteins by Ubc13/Uev1A and TRAFs; (3) binding of TAK1 and IKK complexes to a common scaffold created by K63-linked polyubiquitin chains, which allows activation of TAK1 and subsequent activation of IKK. Although this provides a working model to understand ubiquitin signalling, several mechanistic details of this process remain unknown. In particular, it is not clear how the oligomerization of TRAF proteins activates their ubiquitin ligase activity or how the binding of K63 polyubiquitinated proteins such as RIP1 and TRAF6 leads to the activation of the TAK1 and IKK complexes. Answers to these questions would require in-depth mechanistic studies assisted by biophysical tools.
Genetic studies have largely validated the concept of ubiquitin activation of protein kinases in various signalling pathways involved in innate and adaptive immune responses. However, it is also evident that the extent to which ubiquitination and TAK1 are involved in the activation of IKK and NF-kB depends on cell types and specific stimuli. For example, Ubc13 and TAK1 play an important role in IKK and JNK activation in TCR signalling in thymocytes, whereas the knockout or knockdown of these proteins only blocked JNK but not IKK activation by BCR in mouse B cells. Thus, an important task in the future is to uncover other ubiquitination enzymes and kinases that could mediate IKK activation in specific signalling pathways. For TAK1, it is clear that this is a pivotal kinase that regulates the first step of several phosphorylation cascades, which control a variety of physiological and pathological processes. Unravelling the mechanisms by which TAK1 is activated is key to understanding how signalling cascades are initiated and propagated.
